Bristol Myers Squibb Company $BMY Stock: Roman Butler Fullerton & Co. Trims Holdings

Roman Butler Fullerton & Co. lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 46.6% during the third quarter, Holdings Channel reports. The fund owned 14,516 shares of the biopharmaceutical company’s stock after selling 12,673 shares during the period. Roman Butler Fullerton & Co.’s holdings in Bristol Myers Squibb were worth $854,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Insight Inv LLC increased its stake in shares of Bristol Myers Squibb by 27.5% in the 3rd quarter. Insight Inv LLC now owns 18,756 shares of the biopharmaceutical company’s stock valued at $1,170,000 after buying an additional 4,045 shares during the period. SYM FINANCIAL Corp lifted its stake in shares of Bristol Myers Squibb by 3.7% during the third quarter. SYM FINANCIAL Corp now owns 14,532 shares of the biopharmaceutical company’s stock valued at $907,000 after acquiring an additional 520 shares during the period. Independence Bank of Kentucky boosted its holdings in Bristol Myers Squibb by 5.9% in the third quarter. Independence Bank of Kentucky now owns 8,215 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 459 shares during the last quarter. Angeles Wealth Management LLC boosted its holdings in Bristol Myers Squibb by 1.1% in the third quarter. Angeles Wealth Management LLC now owns 20,995 shares of the biopharmaceutical company’s stock valued at $1,310,000 after acquiring an additional 232 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in Bristol Myers Squibb in the third quarter worth about $237,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Trading Up 0.0%

NYSE BMY opened at $61.63 on Wednesday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The stock has a 50-day simple moving average of $63.09 and a 200 day simple moving average of $59.85.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.51 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date is Friday, October 2nd.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Wells Fargo & Company dropped their price objective on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, October 13th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 13th. Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a research note on Wednesday, August 5th. Finally, William Blair restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $65.50.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Encouraging cancer-drug data strengthens the growth pipeline. Izalontamab brengitecan (Iza-Bren) reportedly doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer. Separate Phase 3 data indicated the drug reduced breast-cancer progression risk by as much as 38%. The results could support a future growth driver as Bristol Myers Squibb manages declines from older products. Iza-Bren lung cancer trial results
• Positive Sentiment: Valuation remains supportive. One analysis argues that BMY still trades below fair value based on expected future cash generation, despite its strong 12-month advance. Analysts also point to growth medicines and higher Eliquis guidance as potential offsets to legacy-portfolio weakness. BMY valuation analysis
• Neutral Sentiment: Third-quarter earnings are the next major catalyst. Preview coverage is focused on revenue trends, Eliquis performance, newer growth products and the pace of decline in older drugs. The market is waiting to see whether operating results support the company’s full-year EPS guidance of $6.75–$7.00. Q3 earnings preview
• Neutral Sentiment: Analyst sentiment is cautious but not bearish. Piper Sandler lowered its price target from $82 to $78 while retaining an Overweight rating, implying further upside. Zacks Research maintains a Hold rating and trimmed its Q3 2027, FY2027 and FY2028 EPS estimates only slightly, to $1.55, $6.23 and $5.21, respectively. Piper Sandler BMY target
• Negative Sentiment: Patent expirations remain the principal risk. Declining sales from key legacy medicines could pressure earnings, and estimates already imply lower profitability in later years. Investors must weigh the pipeline’s commercialization potential against this erosion. BMY bargain or value trap analysis

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.